Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis

被引:86
作者
Brain, Matthew [1 ,2 ,3 ]
Winson, Elizabeth [3 ]
Roodenburg, Owen [1 ,2 ]
McNeil, John [1 ]
机构
[1] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[2] Alfred Intens Care Unit, Melbourne, Vic, Australia
[3] Launceston Gen Hosp, Launceston, Tas, Australia
关键词
Continuous renal replacement therapy; CRRT; Vascular access; Filter life; Femoral; Jugular; Vein; CONTINUOUS VENOVENOUS HEMOFILTRATION; REGIONAL CITRATE ANTICOAGULATION; CRITICALLY-ILL PATIENTS; CENTRAL VENOUS CATHETERIZATION; FEMORAL VEIN CATHETERIZATION; CIRCUIT LIFE; HEPARIN ANTICOAGULATION; NAFAMOSTAT MESILATE; RANDOMIZED-TRIAL; VASCULAR ACCESS;
D O I
10.1186/s12882-017-0445-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimising filter life and performance efficiency in continuous renal replacement therapy has been a focus of considerable recent research. Larger high quality studies have predominantly focussed on optimal anticoagulation however CRRT is complex and filter life is also affected by vascular access, circuit and management factors. We performed a systematic search of the literature to identify and quantify the effect of vascular access, circuit and patient factors that affect filter life and presented the results as a meta-analysis. Methods: A systematic review and meta-analysis was performed by searching Pubmed (MEDLINE) and Ovid EMBASE libraries from inception to 29(th) February 2016 for all studies with a comparator or independent variable relating to CRRT circuits and reporting filter life. Included studies documented filter life in hours with a comparator other than anti-coagulation intervention. All studies comparing anticoagulation interventions were searched for regression or hazard models pertaining to other sources of variation in filter life. Results: Eight hundred nineteen abstracts were identified of which 364 were selected for full text analysis. 24 presented data on patient modifiers of circuit life, 14 on vascular access modifiers and 34 on circuit related factors. Risk of bias was high and findings are hypothesis generating. Ranking of vascular access site by filter longevity favours: tunnelled semi-permanent catheters, femoral, internal jugular and subclavian last. There is inconsistency in the difference reported between femoral and jugular catheters. Amongst published literature, modality of CRRT consistently favoured continuous veno-venous haemodiafiltration (CVVHD-F) with an associated 44% lower failure rate compared to CVVH. There was a trend favouring higher blood flow rates. There is insufficient data to determine advantages of haemofilter membranes. Patient factors associated with a statistically significant worsening of filter life included mechanical ventilation, elevated SOFA or LOD score, elevations in ionized calcium, elevated platelet count, red cell transfusion, platelet factor 4 (PF-4) antibodies, and elevated fibrinogen. Majority of studies are observational or report circuit factors in sub-analysis. Risk of bias is high and findings require targeted investigations to confirm. Conclusion: The interaction of patient, pathology, anticoagulation, vascular access, circuit and staff factors contribute to CRRT filter life. There remains an ambiguity from published data as to which site and side should be the first choice for vascular access placement and what interaction this has with patient factors and timing. Early consideration of tunnelled semi-permanent access may provide optimal filter life if longer periods of CRRT are anticipated. There remains an absence of robust evidence outside of anti-coagulation strategies despite over 20 years of therapy delivery however trends favour CVVHD-F over CVVH.
引用
收藏
页数:27
相关论文
共 104 条
  • [31] Dunn WJ, 2014, CRIT CARE RESUSC, V16, P225
  • [32] Haemodynamic Impact of a Slower Pump Speed at Start of Continuous Renal Replacement Therapy in Critically Ill Adults with Acute Kidney Injury: A Prospective Before-and-After Study
    Eastwood, Glenn M.
    Peck, Leah
    Young, Helen
    Bailey, Michael
    Reade, Michael C.
    Baldwin, Ian
    Bellomo, Rinaldo
    [J]. BLOOD PURIFICATION, 2012, 33 (1-3) : 52 - 58
  • [33] Ede J, 2016, NURS CRIT CARE, V22, P52
  • [34] A comparison of two citrate anticoagulation regimens for continuous veno-venous hemofiltration
    Egi, M
    Naka, T
    Bellomo, R
    Cole, L
    French, C
    Trethewy, C
    Wan, L
    Langenberg, CC
    Fealy, N
    Baldwin, I
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2005, 28 (12) : 1211 - 1218
  • [35] A Comparison of the Niagara™ and Medcomp™ Catheters for Continuous Renal Replacement Therapy
    Fealy, Nigel
    Kim, Inbyung
    Baldwin, Ian
    Schneider, Antoine
    Bellomo, Rinaldo
    [J]. RENAL FAILURE, 2013, 35 (03) : 308 - 313
  • [36] Building and validation of a prognostic model for predicting extracorporeal circuit clotting in patients with continuous renal replacement therapy
    Fu, Xia
    Liang, Xinling
    Song, Li
    Huang, Huigen
    Wang, Jing
    Chen, Yuanhan
    Zhang, Li
    Quan, Zilin
    Shi, Wei
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (04) : 801 - 807
  • [37] Recurring Extracorporeal Circuit Clotting During Continuous Renal Replacement Therapy Resolved after Single-Session Therapeutic Plasma Exchange
    Fueloep, Tibor
    Cosmin, Adrian
    Juncos, Luis A.
    [J]. JOURNAL OF CLINICAL APHERESIS, 2011, 26 (04) : 214 - 215
  • [38] Geddes CC, 1998, CLIN NEPHROL, V50, P320
  • [39] Ghitescu I, 2009, JURNALUL ROMAN ANEST, V16, P17
  • [40] Factors Affecting Circuit Life During Continuous Renal Replacement Therapy in Children With Liver Failure
    Goonasekera, Chulananda D.
    Wang, Justin
    Bunchman, Timothy E.
    Deep, Akash
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2015, 19 (01) : 16 - 22